干眼症的用药研究进展  

Advances in drug use for dry eye disease

作　　者：房淼 王德刚 刘培庆[1] FANG Miao;WANG Degang;LIU Peiqing(School of Pharmaceutical Science,Sun Yat-Sen University,Guangzhou 510275,Guangdong Province,China;Zhuhai United Laboratories Co.,LTD.,Zhuhai 528467,Guangdong Province,China)

机构地区：[1]中山大学药学院,广东广州510275 [2]珠海联邦制药股份有限公司,广东珠海528467

出　　处：《世界临床药物》2022年第5期620-627,共8页World Clinical Drug

基　　金：国家自然科学基金项目(81872860);国家重大新药创制专项(2019ZX09301104);广东省“珠江人才计划”本土创新科研团队项目(2017BT01Y093)。

摘　　要：干眼症(dry eye disease,DED)又称干燥性角膜结膜炎,是由于泪腺分泌不稳定导致泪液质或量异常及眼表损害,致使眼部出现如炎症、疼痛、发红及发痒等多种症状的一种疾病,环境及遗传等因素均可诱发DED。尽管目前已有多种针对DED的药物上市,但产品渗透率较低,因此临床仍有较大需求。该文就目前DED临床用药及全球DED在研药物的研究进展作一综述,以期为临床用药提供参考。Dry eye disease(DED),also known as keratoconjunctivitis sicca(KCS),is a disease caused by unstable lacrimal gland secretion,which leads to abnormal tear quality or quantity and eye surface damage,resulting in a variety of ocular symptoms,such as inflammation,pain,redness and itching.DED can also induce by environmental and genetic factors.Although there are many kinds of drugs for DED on the market,the product penetration rate is low,so there is still a great demand in clinic.This paper reviewed the current clinical drug use of DED and the research progress of global drugs for DED in research,in order to provide reference for clinical drug use.

关 键 词：干眼症 眼表损害 临床用药 

分 类 号：R777.34[医药卫生—眼科]